Adam Crystal, President, R&D at Tango Therapeutics, Inc. (TNGX), sold 27,000 shares at $26.79 ($736K) on 2026-08-03, disclosed to the SEC on 2026-08-05.
Scheduled sale ($736k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.79 | 5,267 | $141K | 19.2% |
| 2 | $27.35 | 21,733 | $594K | 80.8% |
| Total | $27.24 avg | 27,000 | $736K | 100% |
| Filing → |
| TNGX | SELL | 2026-07-02 | $799K | — | Filing → |
| TNGX | SELL | 2026-06-03 | $618K | — | Filing → |
| TNGX | SELL | 2026-05-05 | $573K | — | Filing → |